No benefit in adding Sorafenib to TACE in HCC patients, but SIRT gives 4-fold longer time to progression vs TACE, which means more patients get a transplant. Survival for TACE vs SIRT censors at time of transplant is similar, but I presume that if you factored in the higher transplant rate with SIRT it would win hands down. Interestingly, the 2nd trial couldn't accrue the intended number of patients because they all started demanding SIRT!
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1373-z
Y-90 proven superior to cTACE in randomized trial
http://www.sirtoday.org/y-90-proven-superior-to-ctace-in-randomized-trial/
Add to My Watchlist
What is My Watchlist?